Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents | Zendy

Lorenz Räber | Zendy; Michael Magro | Zendy; Giulio Stefanini | Zendy; Bindu Kalesan | Zendy; Ron T. van Domburg | Zendy; Yoshinobu Onuma | Zendy; Peter Wenaweser | Zendy; Joost Daemen | Zendy; Bernhard Meier | Zendy; Peter Jüni | Zendy; Patrick W. Serruys | Zendy; Stephan Windecker | Zendy

Open Access

Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents

Author(s) -

Lorenz Räber,

Michael Magro,

Giulio Stefanini,

Bindu Kalesan,

Ron T. van Domburg,

Yoshinobu Onuma,

Peter Wenaweser,

Joost Daemen,

Bernhard Meier,

Peter Jüni,

Patrick W. Serruys,

Stephan Windecker

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.058560

Subject(s) - medicine , everolimus , cardiology , drug eluting stent , stent , thrombosis , zotarolimus , drug , restenosis , pharmacology

Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research